The latest PharmaTrac report for December 2025 offers a compelling snapshot of the Indian Pharmaceutical Market (IPM) at a pivotal moment. As the industry navigates post-pandemic normalization, evolving therapy landscapes, and disruptive innovations, the data reveals not just numbers, but narratives of change, challenge, and opportunity. Here’s an analytical breakdown of what the report tells us about the state of Indian pharma—and what lies ahead.
1. IPM Overview: Steady Growth Amid Realignment
The IPM closed MAT December 2025 at approximately ₹2.40 lakh crores, with a realistic growth forecast of 8.2%. Actual performance closely matched projections, reflecting a market that is stabilizing after years of pandemic-driven volatility.
Key takeaway: Growth is now driven by volume recovery, price adjustments, and new product penetration, rather than pandemic tailwinds.
Free Membership Required
You must be a Free member to access this content.
